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vessels, can lead to excessive proliferation. Transient systemic inactivation of monocytes 
and macrophages by liposomal alendronate reduced neointrmal formation and restenosis 
in the stented hypercholesterolemrc rabbit model in a manner that can be used indepen- 
dent of Stent number, positron, or overlap and with possible multiple dosing. 
1078-183 The Endothelial Nitric Oxide Synthase (Glu298Asp and - 
788T>C) Gene Polymorphisms Are Associated With 
Coronary In-Stent Restenosis 
Abuzeid Gamma. Mohamed Elrayess, Charles Knight, Emma Hawe, Kim Fox, Steve 
Humphries, National Heart and Lung Institute and Royal Brompton Hospital, London, 
United Kingdom, British Head Foundation Laboratories for Cardiovascular Genetic 
Studies, UCL Medical School, London, United Kingdom 
Background Coronary stent deployment is a major advance in percutaneous treatment 
of ischaemic heart disease, but 1 O-40% of patients strll develop angiographic restenosis 
by 6 months due to neointimal hyperplasia. Patient-specific factors, includmg genetic fac- 
tors, can contribute to this process. We have conducted a prospective study to examme 
the involvement of genetic risk factors (eNOS, ACE, MMP-3, IL-6, and PECAM-1) in res- 
tenosis followmg coronary stent deployment. 
Methods 226 patients who underwent elective coronary artery stenting to de nova 
lesions in native coronary arteries were studied. 205 (90.7%) patients were restudied by 
coronary angiogram at 6 months and the stented lesions were assessed with automated 
quantitative angiography system. Genotype was determined by PCR and restriction 
enzyme digestion. Results Restenosis rate, defined as 250% diameter stenosis, was 
29.3%. The overall genotype frequency distributions were in Hardy-Weinberg equilibrium 
for all variants. Carriers of the 298Asp allele of the eNOS Glu298Asp polymorphism 
showed a higher frequency of restenosis with an odds ratio of 1.88 (95%CI:1.01-3.51, 
p=O.O43) compared to 298Glu homozygotes. Carriers of the -766C allele of the eNOS - 
786Tz.C polymorphism also showed a higher frequency of restenosis with odds ratio of 
2.06 (95%Cl:l.O8-3.94, p=O.O28). Other studied genes did not show significant associa- 
tion with coronary in-stent restenosrs. 
Conclusions In patients with coronary artery disease, the possession of the 296Asp and 
-7866 variants of the eNOS gene is a risk factor for coronary in-stent restenosis, dsmon- 
strating the importance of the nitric oxide system in restenosis. 
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805-1 Two-Year Follow-Up of the RAVEL Study: A 
Randomized Study With the Sirolimus-Eluting Bx 
VELOCITY Stent in the Treatment of Patients With De- 
Novo Native Coronary Artery Lesions 
Marie-Claude Morice, Patrick Serruys. Costantino Costantini, Egon Wuelfert, William 
Wiins. Jean Faiadet. Antonio Columbo. Giulio Guaoliumi. Ferenc Molnar. Ernest0 Ban , 
Hayashi. Jose Eduardo M. Sousa, Marco Perin, on behalf of the RAVEL Trial 
Investigators, lnstitut Cardiovasculaire Paris Sud. Massy, France 
Background: Sirolimus, a macrocyclic antibiotic and immunosuppressant, causes late 
Gl cell cycle arrest. A pilot study using Sirolimus-eluting stents (SES) to treat coronary 
arten, lesions demonstrated almost no neointimal hvoerolasia at 12 months. Results from 
this study were used to design RAVEL, a multicenter. double blind, two-arm, randomized 
studv assessino safetv and effectiveness of the Sirolimus-elutino Bx VELOCINTU stem 
1  .  
versus the uncoated Bx VELOCITYTM stent (16 mm). Methods: The primary endpoint 
was angiographic late loss at 6 months. The secondary endpoints were major adverse 
cardiac events, target vessel revascularization (n/R), target lesion revascularization 
(TLR) and restenosis rate. Inclusion criteria: stable or unstable angina, single trsatment- 
de nova lesions < 16mm long, 2.5-3.5 mm diameter. Clopidogrel or Ticlodipine was con- 
tinued for up to 8 weeks following a loading dose. Results: From August 2000Decem 
ber 2000. 236 patients were enrolled at 19 sites in Europe and South America. Baseline 
demographics and lesion characteristics were evenly distributed. No acute, subacute or 
late thrombosis occurred. One year results. 
Sirolimus Control P-value 
Reference diameter (mm) 2.60 
MLD Post-procedure (mm) 2.43 
MLD Follow-up (mm) - 6 month 2.42 
Late loss (mm) 0.01 
Restenosis rate (%) 0.0 
TLR-free - 1 year 99.2 
TV&free - 1 year 96.3 
TVF-free - 1 year 95.6 
MACE-free - 1 year 94.1 
2.64 NS 
2.41 NS 
1.64 .OOOl 
0.60 .OOOl 
26.1 .OOOl 
66.0 .OOOl 
64.3 .OOOl 
80.3 .OOOl 
81.2 .OOOl 
Conclusion: The QCA data demonstrate virtually no neointimal in-stent proliferation with 
event-free survival of 94% at one year in the SES treatment group. Two-year clinical fol- 
low-up data will be presented. 
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805-2 Cost-Effectiveness of Sirolimus Drug-Eluting Stents for 
the Treatment of Complex Coronary Stenoses: Results 
From the Randomized SIRIUS Trial 
David J. Cohen, Ameet Bakhai, Chunrue Shi, Lourse Githiora, Ronna H. Berezin, Ronald 
P. Caputo, Charles O’Shaugnessy, Martin B. Leon, Jeff Moses, &chard E. Kuntz, on 
behalf of the SIRIUS Investigators, Beth Israel Deaconess Medical Center, Boston, MA, 
Harvard Clinical Research Center, Boston, MA 
Background: Previous studies have demonstrated that sirolimus drug-eluting stants 
(DES) dramatically reduce angiographic and clinical restenosis compared with conven- 
tional stenting. However, the cost-effectiveness (C/E) of DES in routine clinical practice is 
unknown. Methods: We prospectively measured medical resource utilization and cost 
for 1100 PCI patients randomized to either sirolimus DES or bare stems (BS) as part of 
the SIRIUS trial. Costs were assessed from the U.S. societal perspective, and each DES 
was assumed to cost 53000/stent. Results: Resource utilization and l-year cost data for 
the first 400 randomized patients are displayed below (see Table). Although DES 
reduced the rate of target vessel revascularization by 62% and follow-up costs by 
-$1500/pt, total l-year costs remained higher with DES ($14,245 vs. 513,642, pcO.001). 
The incremental C/E ratio for DES compared with BS was $5542 per repeat revascular- 
ization (RepRev) avoided-- similar to the C/E of BS for de nova lesions or brachytherapy 
for diffuse intrastent restenosis (-$5000 $10,000 per RepRev avoided). 
Conclusions 1) In a representative population of PCI patients, sirolimus DES Improved 
clinical outcomes but increased overall health care costs by -$600/pt compared with BS. 
2) Nonetheless, considering the quality of life benefits of avoiding restenosis. the C/E of 
DES compares reasonably with other accepted interventional techniques. 3) Comolete l- 
year data on the full 1100 pt trial will be available by 3103. 
Number of stentslpatient 
Cath lab cost 
Initial hosp. Cost 
l-year outcomes 
1.1*0.4 
$6225*1365 
510.704*2139 
Repeat revasc. (target vessel) 6.6% 
Repeat revasc (any vessel) 12.6% 
F/U cost 5354123204 
l-year total cost $14,246-3869 
Sirolimus Stent Bsrs Stent 
1.1*0.5 
$4179+1016 
$8611*1913 
17.6% 
23.3% 
$5040*5098 
513,84&5548 
P-value 
NS 
<O.OOl 
<O.OOl 
<O.OOl 
0.006 
<O.OOl 
<0.001 
* Adjusted to account for the availability of stent lengths up to 33mm in clinical practice 
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so5_3 One-Year Follow-Up of the SIRIUS Study: A 
Randomized Study With the Sirolimus-Eluting BX 
VELOCITY in the Treatment of Patients With De- 
Novo Native Coronary Artery Lesions 
David R. Holmes. Jr., Martin B. Leon, Jeffrey W. Moses, Jay Midwall. Mel Clark, lgor 
Palacios, Mark Bates, John Lopez, Alan C. Yeung, Richard E. Kuntz, on behalf of the 
SIRIUS Trial Investigators, Mayo Cknic, Rochester, MN 
Background: The Sirolimus-eluting stent (SES) is emergmg as a potential solution to the 
problem of restenosis in a variety of patient populations. The SIRIUS trial is a 1056 
patient, multicenter, double blind study conducted in the US comparing the Sirolimus- 
eluting stent (SES) to the uncoated Bx VELOCITY (control). The interim results of the 
first 400 patients, previously presented, demonstrated the safety and effectiveness at 9 
months. Longer term follow-up of these patients is planned at 12 months, and annually 
out to five years to confirm the durability of this treatment of de nova native coronary 
artery lesions. Methods: From February to August, 2001, 1058 patients were enrolled at 
53 centers. The primary endpoint was target vessel failure (TVF) at 9 months. Other clin- 
ical, angiographic and IVUS endpoints were also evaluated. Baseline demographics on 
the entire cohort revealed a mean age of 62 years, 26.4% diabetics, 41.6% with multives- 
sel disease, 30.6% had a prior Ml. The average lesion length was 14.4mm and the refer- 
ence vessel diameter was 2.60mm. Results: Nine month clinical follow-up results are 
presented below (Table 1). Accordingly, sirolimus-eluting stents appear to be safe and 
effective at 9 months. Twelve-month clinical follow-up will be presented. 
